Interstitial lung abnormalities: state of the art

A Hata, ML Schiebler, DA Lynch, H Hatabu - Radiology, 2021 - pubs.rsna.org
The clinical importance of interstitial lung abnormality (ILA) is increasingly recognized. In
July 2020, the Fleischner Society published a position paper about ILA. The purposes of this …

Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis

E Suazo-Zepeda, M Bokern, PC Vinke… - Cancer Immunology …, 2021 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) can cause serious immune-related
adverse events (irAEs). This study aimed to identify risk factors for all types of irAEs induced …

[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

JR Brahmer, H Abu-Sbeih, PA Ascierto… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society

H Hatabu, GM Hunninghake, L Richeldi… - The lancet Respiratory …, 2020 - thelancet.com
The term interstitial lung abnormalities refers to specific CT findings that are potentially
compatible with interstitial lung disease in patients without clinical suspicion of the disease …

Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event …

C Chen, B Wu, CY Zhang, T Xu - International immunopharmacology, 2021 - Elsevier
Backgrounds Immune-related adverse events were reported in patients treated with immune
checkpoint inhibitors (ICIs). However, with the increasing number of immune-related …

Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and …

W Zhang, Y Tan, Y Li, J Liu - Frontiers in Immunology, 2023 - frontiersin.org
Background The use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to an
increase in immune-related adverse events (irAEs), which can cause treatment …

Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study

N Okada, R Matsuoka, T Sakurada, M Goda… - Scientific reports, 2020 - nature.com
Immune checkpoint inhibitors (ICIs) elicit antitumour effects by activating the host immunity
and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI …

Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives

S Tomassetti, V Poletti, C Ravaglia… - European …, 2022 - Eur Respiratory Soc
The incidental discovery of pre-clinical interstitial lung disease (ILD) has led to the
designation of interstitial lung abnormalities (ILA), a radiological entity defined as the …

[HTML][HTML] Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer

L Zhou, X Wei - Frontiers in Immunology, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs) are novel immunotherapy-based drugs that have
become increasingly popular in the treatment of lung cancer. Researchers have recognized …

Immune checkpoint inhibitor-related pneumonitis

G Gomatou, V Tzilas, E Kotteas, K Syrigos, D Bouros - Respiration, 2021 - karger.com
Immune checkpoint inhibitors are novel agents that have been proved efficacious in a
variety of cancer types, but they are associated with a unique set of organ-specific, immune …